NASDAQ:OPRX - Nasdaq - US68401U2042 - Common Stock - Currency: USD
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions...
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions...
- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% -...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OptimizeRx (NASDAQ:OPRX) just reported results for the second quarter of 2024.O...
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions...
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology...
The availability of Micro-Neighborhood® Targeting on the Company’s Dynamic Audience Activation Platform meets the demand of life sciences marketers by...
OPRX stock results show that OptimizeRx beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology...
OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide...
OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide
The Company’s AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program...
The Company’s AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program
• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing...